phenotypic analysis of mouse models of human diseases is essential to understanding the underlying disease mechanisms and to developing therapeutics. Many models of neurodegenerative diseases are associated with motor dysfunction, a powerful readout for the disease. We describe here a set of measures to quantitatively monitor early disease onset and progression. We named this set of rules qMotor because it enables sensitive, robust and quantitative measurement of motor performance in 3 d. qMotor can be used to assess early disease onset, before paralysis, as well as disease progression in diverse mouse models, and can be exploited to define robust and humane experimental end points, thereby reducing animal suffering. as an example, we apply qMotor to soD1 G93a transgenic mice. early studies with the original transgenic soD1 G93a mice in the hybrid background (B6sJl-tg(soD1-G93a) have been criticized because of high noise in this mixed background and because of inadequate study designs. We applied qMotor in soD1 G93a transgenic mice in an inbred c57Bl/6J background, hereafter called isoD1 G93a mice, and show a remarkably robust and consistent phenotype in this line that we use to evaluate a therapeutic approach. qMotor is a protocol generically applicable to different mouse models.
IntroDuctIon
Neurodegenerative diseases are devastating and affect an increasing number of individuals in our aging society. Mouse models, recapitulating key features of human neurodegenerative diseases, have been generated and are valuable to the study of disease mechanisms and potential therapeutics 1 . Because no treatments have yet translated to humans to either stop or slow down the progression of these increasingly prevalent neurodegenerative diseases, mouse models have been criticized 1 . Nevertheless, these mouse models develop representative features of the human diseases, and the poor translatability of preclinical studies may well be the result of inadequate study design, rather than flaws in the model per se 1 .
Here we present qMotor, a simple set of measures and rules that enables quantitative and robust assessment of motor performance in transgenic mice, thus facilitating the study of neurodegenerative diseases and the assessment of potential therapeutic approaches.
Rationale for the protocol
Many models of neurodegenerative diseases are associated with motor dysfunction. Thus, assessing motor deficits presents a powerful tool for evaluating potential therapeutic treatments in diverse disease models.
Measures frequently used to detect disease phenotype in SOD1 transgenic mice, such as weight loss or gait analysis, reveal changes at a late stage 2, 3 . Thus, the vast majority of studies conducted before used severe protocols to assess disease onset and progression in SOD1 mice 4 . qMotor is thereby a substantial improvement over existing methods and could be broadly used to detect disease onset before severe paralysis and to conduct robust studies with humane yet robust end points, thereby reducing animal suffering and the numbers of animal used, in line with the principle of the 3Rs (replacement, reduction and refinement).
Distinguishing skill learning and motor performance by rotarod analyses
In the rotarod test, mice are trained to run on a horizontal rotating rod, and the latency to fall is used as a measure of motor ability. Rotarod analysis can be used for two purposes: to study skill learning 5 and to assess motor performance 6 . Performance is known to increase over time during multiple rotarod sessions as training progresses and plateaus after a few sessions 5 . This is the result of motor skill learning and does not reflect fitness 5 . Intersession improvement is known to decrease with the number of sessions 5 . After the initial learning period, rotarod analyses measure motor performance 5 . Thus, it is important to avoid the confounding effect of the motor learning phase to allow quantitative assessment of motor performance by rotarod analyses.
Assessing motor deficits by rotarod analyses
Previously, we have used rotarod analyses to demonstrate the therapeutic efficacy of the selective phosphatase inhibitor Sephin1 in two independent mouse models 3 , using a refined rotarod procedure that we now describe here. We found that Sephin1 prevents motor and molecular defects in a transgenic mouse model of the demyelinating neuropathy Charcot-Marie-Tooth 1B (CMT-1B) 3 . The CMT-1B model, first published in 2006 (ref. 7) , is a robust model of CMT-1B in the FVB/N background, and has been used in numerous studies. Deletion of serine 63 in myelin protein (P0S63del), one of the most abundant proteins made by Schwann cells in the peripheral nervous system, causes the demyelinating neuropathy CMT-1B in humans, by a gain of toxic property because of the misfolding of the mutant protein 7 . Transgenic mice expressing the mutant P0S63del transgene recapitulate key features of the human disease 7 . The CMT-1B mice develop motor deficits owing to myelination defects as a consequence of the misfolding of myelin P zero 7 . Although the CMT-1B mice do not manifest any overt clinical phenotype, repeated rotarod analyses at 4 months of age with 14 CMT-1B mice and 14 wild-type littermates reveal robust deficits in CMT-1B mice 3, [7] [8] [9] .
We also previously reported that Sephin1 prevents the motor and molecular defects of the SOD1 G93A amyotrophic lateral sclerosis (ALS) mouse model. In this study, we found robust phenotypes by rotarod analysis with four or six animals per group 3 , whereas previous guidelines recommended using a cohort of 24 animals per group to evaluate the phenotype in SOD1 transgenic mice 10 . Our previous study 3 demonstrated that rotarod analyses are sensitive and enable the detection of a motor phenotype from an early stage of the disease, before the onset of visible motor defects, and with a smaller number of animals. We describe below the mouse strain that we selected for these studies and the detailed protocol, qMotor, that we established to generate these results 3 . This protocol can be used with diverse mouse lines to generate robust results with a reduced number of animals.
Mouse strain selection
To establish the procedure, we recommend testing transgenic mice with motor deficits of different severities together with their wild-type, aged-matched littermates. Among the diverse models of neurodegenerative diseases, the transgenic SOD1 G93A mouse model is particularly attractive, as it faithfully recapitulates many defining features of ALS: the misfolding of the disease-causing protein, motor defects due to motor neuron loss, hind-limb paralysis and neuroinflammation 11, 12 .
The original SOD1 G93A strain is maintained by crossing transgenic hemizygous males with female C57BL6SJL/J hybrids. This model has been widely criticized because no studies performed in this model have yet translated to humans 10, 13 . However, because ALS still represents an unmet medical need, and the mouse models recapitulate key features of the human disease, it seems unreasonable to dismiss the potential usefulness of this model.
Methodological limitations of the studies relying on the SOD1 G93A line in a mixed background have been highlighted previously, and some guidelines have been published to overcome them 10, 13 . However, despite the fact that mixed backgrounds are notorious for introducing major variability, the importance of the mixed background as a confounding factor in animal studies is overlooked, and most studies continue to use the SOD1 G93A in the mixed C57BL6SJL/J background. To circumvent these limitations, SOD1 G93A transgenic mice have been produced in a pure C57BL/6J background (hereafter called iSOD1 G93A ). This line exhibits an extremely robust disease progression with very little background noise and remarkable consistency in intra-and interstudy data from different laboratories 2, 3 , as long as the transgene copy number remains constant in the colony and in the experimental group. This latter caveat is controlled by analyzing the transgene copy number.
Although SOD1 mutations account for only a subset of familial forms of ALS, studying rare forms of a disease may shed light on mechanisms or therapeutic strategies that may be relevant to more common diseases. Here we provide a robust protocol for monitoring the motor deficits in iSOD1 G93A mice. This protocol is applicable to diverse mouse models.
In the B6SJL-Tg(SOD1-G93A)1 model, previous guidelines recommended using a cohort of 24 animals in each group (wildtype and transgenic) 10 . The robustness of the phenotype in the iSOD1 G93A line implies that the number of animals required for a conclusive study could be substantially reduced 2 . Moreover, previous guidelines used death or extremely severe phenotypes as an end point 10 . These guidelines need to be revised to comply with the European Union directive on animal research (Directive 2010/63/EU, Article 13.3 http://eur-lex.europa.eu/legal-content/ EN/TXT/?uri=CELEX:32010L0063), which states that 'death as an end point to a procedure should be avoided as far as possible and replaced by earlier, humane end points'. This is in line with the principle of the 3Rs and with the regulation on the use of animals in research (Animals (Scientific Procedures) Act 1986; https://www.gov.uk/government/publications/consolidated-version-of-aspa-1986).
In contrast to the CMT-1B mice, the iSOD1 G93A transgenic mice develop hind-limb paralysis with 100% penetrance after 12 weeks 2,3 . The motor phenotype of the iSOD1 G93A transgenic mice is severe, suggesting that it should be possible to reliably and quantitatively measure the motor deficits in iSOD1 G93A mice by rotarod analyses with fewer mice than are required to quantify the motor defects in CMT-1B mice, which do not develop any visible symptoms. Moreover, the ability to detect motor deficits in CMT-1B in the absence of visible symptoms suggests that it should be possible to detect the early stage of the disease in iSOD1 G93A transgenic mice, before the onset of paralysis observed at 12 weeks in this line 3 . Detecting motor deficits before paralysis represents an attractive possibility that could lead to defining humane end points, thereby refining protocols and reducing animal suffering.
Overview of qMotor
The essential refinements of the rotarod procedures leading to qMotor consist of increasing the trial duration and increasing the number of trials. This protocol may be longer than previous protocols, but it generates robust results with fewer animals. Traditionally, rotarod analyses with SOD1 mice are performed with three trials that record the latency to fall from an accelerating rotarod (4-40 r.p.m.), with a trial duration of 150-180 s 14 . By contrast, rotarod analyses with CMT-1B mice are traditionally performed with six sessions of three trials. Each session lasts 900 s: 300 s of acceleration (4-40 r.p.m.) followed by 600 s at 40 r.p.m. 3, 7 . As previously observed 7 , the mice improve their performances during the first three sessions, as training progresses (Fig. 1) . After the fifth session, improvements plateau (Fig. 1 , ref. 5 ). Consequently, the motor deficits of CMT-1B mice are not observed in the first three sessions, as these are confounded by the learning phase, but they became apparent after the fourth session 7 (Fig. 1) . Similarly, when looking at the therapeutic benefit of Sephin1, it is not detectable for the first three sessions but is evident and robust after the fourth session in both female and male animals ( Fig. 1; Supplementary Fig. 1; Supplementary Table 1) . These example results illustrate that repeated rotarod analyses can be used to quantitatively assess motor deficits in the absence of a visible phenotype and demonstrate that trial duration and number of trials can have an influence on rotarod tests.
Knowing that we can quantitatively assess the motor deficits of CMT-1B mice in the absence of a visible motor phenotype, we reasoned that rotarod tests with iSOD1 G93A mice could be improved by increasing trial duration and number of trials. In a previous study 3 , we therefore tested iSOD1 G93A mice and wild-type littermates (n = 4-6 mice per group) using a refined rotarod procedure consisting of a 3-d trial, with three trials per day 3 (Fig. 2) . Here we present the different trials from our previous study 3 . The duration of each trial was set at 300 s based on pilot experiments showing that this duration was sufficient to reveal the phenotype of iSOD1 G93A mice before the onset of paralysis. We performed rotarod tests with iSOD1 G93A mice and wild-type littermates at 60 d of age and noticed, as previously reported 5 , that performance improved with the number of sessions ( Fig. 3a; Supplementary  Table 2 ). Because previous studies have shown that the improvement in rotarod performances plateaus after five to six trials 5 , this learning period must be excluded from experimental tests aimed at assessing motor performances. In a typical experiment, after the learning period, the motor defects in iSOD1 G93A mice are robust and consistent in the three trials (Fig. 3a) . Here we reanalyzed our previously published study 3 by separating genders and found that the phenotype was similarly robust in both genders (Supplementary Fig. 2; Supplementary Table 2) . Rotarod tests performed on a separate cohort of wild-type and iSOD1 G93A mice at 90 d of age confirmed that the motor deficits in iSOD1 G93A were recapitulated in both male and female mice (Supplementary  Fig. 3; Supplementary Table 3 of quantitatively assessing motor defects in iSOD1 G93A mice with a small number of mice, before the visible paralysis.
Using qMotor to test drug efficacy
The procedure can be used to assess the efficacy of drugs over time. We show results obtained from treating iSOD1 G93A mice with Sephin1 over time as determined by rotarod analyses (Fig. 3b) . This figure represents the different trials of our previous study 3 . Four experimental groups were used, which were composed of randomized iSOD1 G93A mice and wild-type littermates treated with Sephin1 (5 mg/kg, once per day) or vehicle from 4 weeks of age. As noted above, the first six sessions (days 1 and 2) of the rotarod tests are excluded from analyses aimed at measuring motor performances because of the confounding effect of the learning phase 5 . Rodents retain rotarod skills after they have learned them 5 (Fig. 3b) , so there is no need for additional training periods, even after a month without training. After the learning phase in the first two trial days, the subsequent trials are remarkably consistent in all four groups (Fig. 3b) . This demonstrates that qMotor is extremely robust to measurement of motor defects in iSOD1 G93A mice and further underscores the robustness and consistency of the motor phenotype in iSOD1 G93A mice. The efficacy of drugs can also be tested; for example, qMotor was used to test the efficacy of Sephin1 iSOD1 G93A mice 3 . We observed robust differences between the iSOD1 G93A mice treated with Sephin1 and those treated with vehicle, using four or six mice in each group 3 . These differences were highly significant on each trial day (P ≤ 0.01). day 62, days 90-92 and days 110-112 (Fig. 3b) . We reanalyzed our published results, separating genders, and found that similar results were obtained for both genders (Supplementary Fig. 2 ). These results demonstrate that qMotor revealed motor deficits in iSOD1 G93A mice, with very little inter-cohort variation. These results highlight the robustness of the method, the predictability of motor deficits in this mouse line and the potency of the treatment. uk/government/publications/code-of-practice-for-the-housing-and-care-of-animals-bred-supplied-or-used-for-scientific-purposes), or the relevant local and national guidelines and regulations.
MaterIals

REAGENTS
•
We keep mice in specific pathogen-free ventilated cages (Tecniplast) on Lignocel FS14 spruce bedding (IPS) and Enviro-Dri nesting material (LBS) at 19-23 °C with a 12-h light-dark cycle, with light from 7:00 a.m. to 7:00 p.m. We feed our experimental animals Dietex CRM pellets. The maximum number of male mice housed in an individual cage is 4 and the maximum number of female mice is 5 in accordance with animal care and use regulations. To monitor health conditions, check all experimental animals visually every day, clean out cages when soiled and perform a physical health check each week on all mice. Weigh the experimental animals weekly. We provide experimental animals reaching the moderate severity of disease limit with mash (Dietex CRM pellets soaked in water). Generation of mice The CMT-1B mice are transgenic for mutant myelin protein zero with deletion of serine 63 (P0S63del) and are maintained in the FVB/N background 7 . We use hemizygous male and female CMT-1B mice and age-matched wild-type littermates in experiments. SOD1 mutant mice iSOD1 G93A are maintained in a C57BL/6J background. Experimental animals are generated by crossing hemizygous iSOD1 G93A male mice with C57BL/6J female mice. The disease phenotype is extremely robust in this line, and remarkably similar to that in the iSOD1 G93A C57BL/6J line 2 , when the transgene copy number remains constant. The robustness and penetrance of the phenotype enable the rapid identification of mice with reduced transgene copy number, because this leads to a loss or reduction of phenotype. We observed this once since we obtained this line in 2011. Genotyping and copy number analysis Identify mice by ear clipping and retain the ear tissue for extraction of genomic DNA using the TaqMan Sample-to-SNP Kit. Genotype CMT-1B mice as described elsewhere 7 . Perform genotyping PCRs on genomic DNA in a 10-µl volume with 500 nmol each of the following human SOD1 primers: IMR002, ctaggccacagaattgaaagatct; IMR0043, gtaggtggaaattctagcatcatc; IMR0113, catcagccctaatccatctga; and IMR0114, cgcgactaacaatcaaagtga. After PCR, visualize the products using a QIAxcel DNA Fast Analysis Kit (3000). The wild-type band is at 324 bp and human SOD1 G93A is at 236 bp. Perform transgene copy number analysis by quantitative PCR. We use 12.5 ng of cDNA, SYBR select Master Mix on a Corbett Rotor-Gene version 6000, using human SOD1 G93A primers, forward: gtgtgcgtgctgaagggcga, and reverse: ccacctttgcccaagtcatctgc, in a total volume of 12.5 µl. Compare ∆∆Ct values with a reference cDNA sample containing only two copies of human SOD1. Allocation of animals to experimental groups Sex-and age-matched transgenic male and female mice and their wild-type littermates should be used in experiments. Litters should be randomized using any randomization software (e.g., those found at http://www.random.org) to create cohorts of the placebo and treatment experimental groups. Sample size Determine animal cohort numbers using either previous studies 7 or preferably a priori power calculation on pilot experiments ( Supplementary Fig. S6 in ref. 3) .
proceDure experimental setup
To set up each day of testing, keep mice in their home cages and move the cages to the testing room to allow the mice to become acclimatized to the testing room for at least 60 min.  crItIcal Timing should be such that tests are performed during the light cycle. 1| Tail-mark the mice with nontoxic red ink (assign marks such as I, II, III, IV, V).  crItIcal step Do not mix the genders in the same run. Mice behavior might be affected when genders are mixed. Always start with male animals before female animals.
Habituation
2|
For habituation, place the animal for 1 min on a static rotor and then for 1 min at a constant speed (4 r.p.m.). After waiting at least 10 min, repeat this step (Fig. 2a) .  crItIcal step Habituation is performed only once before carrying out the first trial on the first day.
3|
Return the mice to their home cages and return mice to their home environment or proceed with Step 6.
4|
Clean the rotarod machine with 70% EtOH after each group of mice. learning phase 5| Transfer mice to the testing room at least 1 h before testing, keeping mice in their home cages.
6|
Place mice on the rod so that they run forward, and set the apparatus to accelerating mode (4-40 r.p.m. in 300 s) and record the latency to fall. The upper limit of 300 s per trial was found optimal for the iSOD1 G93A line but may vary between different mouse models.  crItIcal step The trial duration may differ between different mouse models. In the iSOD1 G93A mice used here, the 300-s duration in rotarod tests is such that the average latency to fall of wild-type mice, after the learning period (after the increase in performance between sessions reaches a plateau), is 50 s below the maximum trial duration. In pilot experiments, tests can be carried out with mice with and without motor deficits (transgenic mice and wild-type age-matched littermates, in the examples used) on an accelerating rotarod (4-40 r.p.m.) for a duration of 300 s. If repeated trials under these conditions fail to detect the phenotype, the duration of the trials may be extended to 600 and 900 s, continuing with a constant speed of 40 r.p.m. As shown here, the optimal cutoff time varies between different models but is consistent within the same line, with very little intra-or inter-cohort variation, as exemplified here in the different experiments presented. ? trouBlesHootInG 7| Clean the apparatus with 70% EtOH after each run.  crItIcal step For unbiased results, the machine should be cleaned after each group of mice.
8|
Repeat Steps 6 and 7 twice, providing at least a 15-min interval between trials for each mouse.  crItIcal step The number of learning trials may be increased if the mice have motor deficits. The learning is considered complete when the increase in performance after each session reaches a plateau.
9| Return mice to home cages and home environment overnight.
note: Mice remember the motor skills after the initial learning period. Thus, in longitudinal studies, the learning trials are only performed once, before the first test. testing phase 10| Repeat Steps 5-8 over three trials performed over three consecutive days. Thus, in total, nine trials should be performed to assess motor performance at a given time (Fig. 2b) . All experiments should be carried out at 4-40 r.p.m. over 300 s for iSOD G93A mice and over 900 s (300 s 4-40 r.p.m. and 600 s 40 r.p.m.) for CMT-1B mice. Perform trials as described in the Learning phase section, with a minimum of 15 min between trials.
 crItIcal step The duration of the entire protocol (learning and testing) depends on the severity of the motor deficits of the mice, which determines the duration of the trial, and also on the number of animals. For example, in an experiment with an acceleration time of 300 s per trial, as in iSOD G93A mice, testing one set of mice (five animals) takes in total 1 h on three consecutive days, including the resting intervals. For one experiment with a group of 40 mice, the required trials will take a minimum of 2 h (running new groups during the resting intervals of previous groups). When testing mice with mild motor deficits, such as CMT-1B mice, the duration of the trials may be longer. In the case of CMT-1B mice, the duration of experiments is ~6 h for 40 mice per day. analysis 11| Analyze the data using two-way repeated-measures ANOVA and a Bonferroni post hoc procedure to correct for multiple comparisons (GraphPad Prism software). The level of significance can be set at P < 0.05, P < 0.01, P < 0.001 or P < 0.0001. No samples, mice or data points should be excluded from the analyses.
12|
The ARRIVE guidelines must be followed when reporting animal studies 15 .  crItIcal step The first trials corresponding to the learning phase on the rotarod (until the performance reaches a plateau) should be excluded from quantitative analysis in order to assess motor performance without the confounding effect of the motor learning phase. ? trouBlesHootInG Mice might cling to the rod instead of falling. If mice perform two full passive rounds clinging to the rod, this indicates a failure of motor function. When this happens, stop the trial for this mouse by pushing down the lever and record the time. Any excluded mice must be reported.
• tIMInG Testing one set of mice (five animals) takes 20 min for habituation (Steps 2-4) and 45 min for three trials (Steps 5-9 or
Step 10) each day.
antIcIpateD results
By optimizing trial duration and by repeating rotarod analyses, we find that rotarod measures are extremely robust and enable assessment of motor disease with a reduced number of animals. The motor deficits may not be observed in the first trials but become apparent and robust upon repeated trials (Figs. 1 and 3) , with a relatively smaller number of animals than are used with other methods. The quantitative nature of qMotor allows for the measurement of drug efficacy in different mouse models (Figs. 1 and 3) . Importantly, the sensitivity of this method is such that it allows detection of motor deficits in the absence of visible symptoms (Figs. 1 and 3) . qMotor can therefore be used to define humane end points in experiments, thereby enabling the refinement of protocols and reducing animal suffering and animal numbers. This method is applicable to many different disease models associated with motor deficits.
